Key findings at a glance For many people, injections are still the biggest barrier: A large number of eligible UK adults say they have avoided GLP-1 treatments because they do not want to inject themselves
Adults with a BMI of 27 or higher who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol
A good appeal usually includes: The denial letter language: so your response addresses the exact objection A concise clinical summary: short, specific, and aligned with the payers criteria Objective evidence: BMI trend, labs, medication history, and diagnosis documentation Any omitted records from the first submission: many denials happen because key pages were never attached This is also where understanding the role of pharmacy benefit managers can help
Hers takes the FDA-approved brand-name GLP-1 medication approach, while Willow focuses on non FDA-approved, personalized compounded GLP-1 medications